Navigation Links
Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint

effects in both study arms. In addition, there was no statistically significant difference in the primary endpoint between patients receiving nesiritide compared to patients receiving placebo infusions when each was added to optimal heart failure medications, significant use of indicated heart failure devices and intensive disease management.

"The safety findings from the FUSION II trial and other recent clinical studies should be reassuring for physicians who use nesiritide to treat patients according to its currently labeled indication and who are evaluating the drug in ongoing investigations," said Clyde W. Yancy, M.D., Principal Investigator of FUSION II and Medical Director of the Baylor Heart and Vascular Institute at Medical Center at Dallas. "The relatively low clinical event rates observed in both treatment groups are consistent with previous investigations that have demonstrated the utility of rigorous disease management employing optimal medical and device therapies in the improvement of patient outcomes. This is an important message for practitioners."

In multiple rigorously-controlled clinical trials published in peer- reviewed medical journals, NATRECOR(R) was shown to significantly reduce pulmonary capillary wedge pressure and improve patient-reported dyspnea, an important symptom to relieve in patients with exacerbations of heart failure. Since NATRECOR(R) was approved by the FDA in August 2001, more than 800,000 ADHF patients in the United States have been treated with the drug.

FUSION II Study Design and Results

As a follow-up to the FUSION I study, which showed promising initial results in the advanced CDHF patient population, in March 2004 investigators began the prospective, randomized, placebo-controlled, double-blind, multicenter FUSION II trial to further assess the long-term outcomes in this patient group. The study enrolled 920 patients with advanced CDHF at more than 150 sites in the United States and abroad an
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product

Post Your Comments:
(Date:11/6/2009).../ -- California American Water has designated the ...in" week for its San Diego County service area as ...d private agencies alike toward the common mission...e water supplies. ,, California American Water,...p off expired or unwanted pharmaceuticals free of ...
(Date:11/5/2009)...e/ -- Althea Technologies, Inc., a leading provide...opharmaceutical products announced the addition of...,s platform of services, which will be overseen by...of Formulation Development. This investment in an ...entists, along with new laboratory facilities and ...
(Date:11/5/2009)...ire/ -- ARKRAY, Inc., the world,s 5th largest manu...y announced that it has received 510(k) clearance ...ew GLUCOCARD Vital blood glucose monitoring system...KRAY will make available for distribution in early...ent to the existing GLUCOCARD line of products, an...
Breaking Medicine Technology:California American Water Celebrates 'No Drugs Down the Drain' Week in San Diego 2Althea Technologies Adds Formulation Development to Its Integrated Offering of Contract Services 2ARKRAY, Inc. Receives FDA Clearance for New GLUCOCARD(R) Vital(TM) Blood Glucose Monitoring System 2Pelosi Remarks at Press Conference on Health Care Reform for the Middle Class 51551 1Pelosi Remarks at Press Conference on Health Care Reform for the Middle Class 51551 2Pelosi Remarks at Press Conference on Health Care Reform for the Middle Class 51551 3Pelosi Remarks at Press Conference on Health Care Reform for the Middle Class 51551 4Why African Americans are at greater risk of hypertension and kidney disease 51546 1Why African Americans are at greater risk of hypertension and kidney disease 51546 2American Red Cross President to Address National Press Club Luncheon 51542 1American Red Cross President to Address National Press Club Luncheon 51542 2
...n Tourism Commission,launched its new free online ...Care) this week on http://www.OregonQCare.com ., ...pport the tourism and,hospitality industry through...mportance of quality customer service, the trainin... better serve Oregon,s visitors., "We,ve all hear...
... Pharmaceuticals Inc.,presented data at the Sevent...Cancer in Washington, D.C., announcing the discove...demonstrate significant anticancer,activity in pre...lar scaffold has been developed using,computationa...se inhibitors,as well as isoform-selective small m...
Other Medicine Technology:Oregon Tourism Commission Unveils New Online Customer Service Training Program 2Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 2Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 3
(Date:11/8/2009)...her Costs and Crushing Taxes Nail Nation,s Job Cre...ire/ -- In response to U.S. House passage of the h...Entrepreneurship Council (SBE Council) president &...ment: ,, "Make no mistake, those voting for H....with higher costs and crushing taxes and penalties...
(Date:11/8/2009)... Freeze-drying of biopharmaceutica...uga, Ontario facility. , ...llner, President and CEO of Therapure Biopharma In...very of a commercial scale pharmaceutical grade fr...eeze drying (lyophilization) available for contrac...
(Date:11/8/2009)...tion,s largest network of Hispanic health advocate...form in 2009 ,, WASHINGTON, Nov. 7 /PRNewswire...ntatives showed they have heard the voice of Ameri...e for America Act. Now the Senate must deliver, wi...are reform," said Dr. Jane L. Delgado, President a...
(Date:11/8/2009)...RP Praises House Passage of Health Care Reform Bil...dicare, improve coverage for all Americans ,, ...the United States House of Representatives passed ...legislation that would strengthen Medicare for sen... that prices millions of Americans out of affordab...
(Date:11/7/2009)...HINGTON , Nov. 7 Spe...n support of H.R. 3962, the Affordable Health Care...slation later tonight. Below are the Speaker,s re...w, is an historic moment for our nation and for Am... every party and political philosophy -- as far ba...
Breaking Medicine News(10 mins):Health News:Therapure Biopharma Inc. Announces Delivery of its First Commercial-Scale Lyophilizer 2Health News:National Alliance for Hispanic Health President and CEO Applauds House Action, Calls on Senate to Pass Health Reform in 2009 2Health News:AARP Illinois Key Vote News Alert 2Health News:AARP Illinois Key Vote News Alert 3Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 2Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 3Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 4
...on of leading European breast cancer organizations... of scientific conference, which aims to ensure br...e from cutting-edge research. , At the first IMPA...plement their results will discuss how to bring em...
...Industry Veteran Will Focus on Broader Product Dis...SAN FRANCISCO, March 31 DecisionView, Inc., the l... for the Life Sciences industry, today announced t...ently, he held the role of Chairman for DecisionVi...
...CAN HAVE COMPLETE CONFIDENCE IN THE SAFETY AND SEC...RDS , , LOS ANGELES, March 31 MMR Information Sy...ugh its wholly-owned operating subsidiary, MyMedic... deposit box storage solutions ( www.myesafedepos...
... Marketing Technology Solutions (MTS... the company,s new Chief Executive Officer. MTS i...eting and specializes in connecting engaged health...s strong financial performance to date. , ...
...oftware helps small corporations keep compliant wi...Iccomplish, Inc announces the availability of "Qui...the tediousness out of corporate record-keeping an...n of the cost of hiring a corporate attorney. , ...
...rch Releases Study showing state of the senior hea...esearch recently released the 2009 Senior Market ...pping behavior in the senior health insurance mark...rance. The study found that at a $5 dollar premium...
Other Medicine News:Health News:IMPAKT Breast Cancer Conference 2Health News:DecisionView Board of Directors Appoints James P. Scullion as CEO and President 2Health News:MyMedicalRecords Offers Privacy Insurance on Personal Health Record and Virtual EsafeDepositBox Products 2Health News:MyMedicalRecords Offers Privacy Insurance on Personal Health Record and Virtual EsafeDepositBox Products 3Health News:MyMedicalRecords Offers Privacy Insurance on Personal Health Record and Virtual EsafeDepositBox Products 4Health News:Marketing Technology Solutions Primed for Future Growth with Appointment of Rob Rebak as New CEO 2Health News:Marketing Technology Solutions Primed for Future Growth with Appointment of Rob Rebak as New CEO 3Health News:Automate Corporate Minutes and Resolutions; Stop IRS Woes Before They Happen 2Health News:Changes in Medicare Advantage Reimbursement May Prompt Members to Shop for New Plans 2
ACULAR® 5 mL
cardiofax GEM Basic-level interpretive resting ECG
cardiofax Q Mid-level interpretive resting ECG
Cruise Control
Medicine Products: